Top of page

DIRECT: A study looking at genetic changes in diffuse large B-cell lymphoma and other types of high-grade B-cell lymphoma

This study does not involve any treatment. The researchers need blood and biopsy samples from people with fast-growing (high-grade) B-cell lymphomas that they can use for research.

You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT04226937


Trial aim and background

The aim of this study is to find out if particular genetic changes in lymphoma cells can help doctors work out the most suitable treatment for people who have DLBCL or other types of high-grade B-cell lymphoma. It is also testing whether the levels of lymphoma DNA in your bloodstream can be used to measure how well the lymphoma is responding to treatment.

If you take part in this study, you have the usual treatment recommended by your medical team for your type of lymphoma. You also have blood tests:

  • before you start treatment
  • during the first three cycles of your treatment
  • at the end of your treatment
  • 6 months after the end of your treatment
  • 12 months after the end of your treatment.

If your lymphoma comes back (relapses) or gets worse after you finish your treatment, you will have more blood tests.

Researchers will also run tests on the biopsy sample you had when you were diagnosed with lymphoma. If your lymphoma comes back and you have another biopsy, they will test this, too. Some people might have another biopsy as part of the study, but this isn’t needed in most cases.


Who can enter

Adults with DLBCL or other high grade lymphomas who have not had any previous treatment may be eligible for this trial.Your consultant can give you advice on whether you might be suitable for this trial.


Locations

Recruitment is taking place at the Cambridge University Hospitals NHS Foundation Trust, Cambridge


Further information

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: <link to clinicaltrials.gov page>

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.